× Medicines Discovery Catapult

MDC Connects is a series of informative webinars covering the drug discovery process, from our own experts and experts at our CRO network partners.

Understanding the pharmacokinetic-pharmacodynamic (PK-PD) relationship in preclinical models is crucial to predicting an efficacious dose regime in man. Preclinical PK-PD analysis investigates the dose-response relationship of exposure and biological effect.  The exposure levels of a drug following dosing is quantified using PK analysis in the plasma or target tissue and the measurement of a PD marker show how the drug is acting at the biological target.

In this webinar, Graham Trevitt from XenoGesis describes and explains the principles of PK-PD modelling, how it can be applied in early stage drug discovery and how it supports decision making throughout the life time of the project, increasing in complexity and accuracy with time. Jenny Worthington from AxisBio outlines what a successful PK-PD study should include and draws on case studies to demonstrate the benefit of PK-PD models prior to efficacy studies in preclinical animal models; and finally Neill Gingles from MDC describes the approaches for evaluation of PD endpoints, using non-invasive imaging modalities to visualise and quantify clinical response to a drug.


Recording

YouTube video

Slides

Principles and modelling of pharmacokinetic and pharmacodynamic relationships at XenoGesis

Understanding PK/PD using pre-clinical models: Lessons for efficacy studies at AxisBio

Evaluation of clinical and pre-clinical pharmacodynamic endpoints using non-invasive imaging modalities at MDC

Share